---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-016385"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:47:59.577684+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INmune Bio advances CORDStrom in UK, secures FDA alignment for XPro1595 Alzheimer's program

## Summary
- Submitted CORDStrom pre-submission package to UK MHRA for RDEB; targets full MAA filing mid-summer 2026.
- FDA aligns on integrated Phase 2b/3 design for XPro1595 in early Alzheimer's; CDR-SB sole primary endpoint.
- Phase 2b portion to enroll ~300 patients over 9 months; full program ~1,000 participants over 18 months.
- Biomarker-driven enrichment strategy (hsCRP, ESR, HbA1c, APOE4) accepted; exploratory non-enriched cohort included.
- CORDStrom also benefits from reauthorized Rare Pediatric Disease PRV program through 2029.

## SEC filing metadata
- accession: 0001213900-26-016385
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390026016385/0001213900-26-016385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390026016385/ea0276865-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-016385
- JSON: https://secwatch.observer/filing/0001213900-26-016385.json
- Plain text: https://secwatch.observer/filing/0001213900-26-016385.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.